Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.6%

3 terminated/withdrawn out of 65 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

9%

6 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

35 recruiting1 with results

Enrollment Performance

Analytics

N/A
22(52.4%)
Phase 2
14(33.3%)
Phase 3
5(11.9%)
Phase 4
1(2.4%)
42Total
N/A(22)
Phase 2(14)
Phase 3(5)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials
NCT07236840Recruiting

Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors

Role: lead

NCT03997110Not ApplicableRecruiting

Palliative Radiation for Advanced Cervical Cancer

Role: collaborator

NCT06442748Phase 3Recruiting

Short Versus Long-term Levetiracetam in Brain Tumors

Role: lead

NCT07395635Not ApplicableRecruiting

Phase II Trial of Immunonutrition in Hepatectomy

Role: lead

NCT07338526Not ApplicableRecruiting

Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

Role: lead

NCT07338539Phase 2Recruiting

BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM

Role: lead

NCT07337850Recruiting

Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers

Role: lead

NCT05856305Phase 2Active Not Recruiting

SCRT in TNT With or Without Chlorophyllin

Role: lead

NCT06492486Phase 2Not Yet Recruiting

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Role: lead

NCT06831461Not ApplicableRecruiting

Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors

Role: lead

NCT04932564Phase 2Terminated

Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

Role: lead

NCT06058572Phase 2Recruiting

Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia

Role: lead

NCT05774483Not ApplicableRecruiting

Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative

Role: collaborator

NCT07062263Phase 3Recruiting

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

Role: lead

NCT07021677Phase 2Recruiting

Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

Role: lead

NCT05857631Not ApplicableRecruiting

Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

Role: lead

NCT06779487Recruiting

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

Role: lead

NCT06381531Recruiting

Tracing Brain Tumors Through Deep Time

Role: lead

NCT04250064Phase 2Recruiting

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

Role: lead

NCT06214572Phase 2Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer

Role: lead